Achieve Life Sciences, Inc. (ACHV)

Market Cap	230.50M
Revenue (ttm)	n/a
Net Income (ttm)	-52.35M
Shares Out	53.23M
EPS (ttm)	-1.35
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	222,954
Open	4.350
Previous Close	4.400
Day's Range	4.265 - 4.390
52-Week Range	1.840 - 5.780
Beta	1.69
Analysts	Strong Buy
Price Target	12.00 (+177.14%)
Earnings Date	Nov 6, 2025

About ACHV

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Richard A. Stewart
• Employees: 25
• Stock Exchange: NASDAQ
• Ticker Symbol: ACHV
• Website: https://www.achievelifesciences.com

Analyst Summary

According to one analyst, the rating for ACHV stock is "Strong Buy" and the 12-month stock price target is $12.0.

Price Target

$12.0

(177.14% upside)

Analyst Consensus: Strong Buy